Post-Marketing Observational Study to Evaluate the Occurrence of Acute Myocardial Infarction in Adults 18 Years of Age and Older Who Receive HEPLISAV-B Compared with Another Hepatitis B Vaccine

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 12 Nov 2020

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Adjuvanted Hepatitis-B vaccine (Recombinant)-Dynavax (Primary) ; Hepatitis B vaccine recombinant (Primary)
Indications Hepatitis B
Focus Adverse reactions
Sponsors Dynavax Technologies

05 Nov 2020 According to a Dynavax Technologies media release, final report from this study is expected in Q2 2021.
06 Aug 2020 According to a Dynavax Technologies media release, the company expected completion of safety follow-up in the fourth quarter.
11 Mar 2020 According to a Dynavax Technologies media release, completion of this study is expected by Q4 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com